

18 September 2017

Dear Shareholder,

Notification to ineligible shareholder

Analytica Limited (**Company**) today announced that it is undertaking a renounceable pro-rata entitlement offer to eligible shareholders to raise approximately \$1.593 million (before offer costs) (**Entitlement Offer**).

The Offer comprises:

- **(New shares)** 1 new share for every 8 existing shares held at 7.00pm on Thursday, 21 September 2017 (**Record Date**) at an offer price of 0.5 cents per new Share; and
- **(Attaching Options)** for every share allotted under the Entitlement Offer, the applicant will receive 2 options comprising:
 - i. 1 option expiring on 31 January 2018 and exercisable at 0.5 cents; and
 - ii. 1 option expiring on 31 May 2018 and exercisable at 0.5 cents.(together called the **Attaching Options**). No application will be made for the Attaching Options to be listed on ASX.

This letter is to inform you that, unfortunately, you are not eligible to participate in the Entitlement Offer.

You are not required to do anything in response to this letter.

Why am I not eligible to participate in the Entitlement Offer?

Shareholders who are eligible to participate in the Entitlement Offer (**Eligible Shareholders**) are those persons who:

- are registered as a holder of ordinary shares as the Record Date;
- have a registered address on the Company's register of members in Australia or New Zealand;
- are not in the United States and are not a U.S. Person and are not acting for the account or benefit of a US Person; and
- are eligible under all applicable securities laws to receive an offer under the Offer.

The Company has determined, under ASX Listing Rule 7.7.1(a) and section 9A(3) of the *Corporations Act 2001* (Cth), that it would be unreasonable to make offers to shareholders in all countries in connection with the Entitlement Offer due to the number of shareholders outside of Australia and New Zealand, the number and value of shares held by those shareholders and the potential cost of complying with regulatory requirements in those countries.

Unfortunately, according to our records, you do not satisfy the eligibility criteria for an Eligible Shareholder stated above.

Accordingly, in compliance with ASX Listing Rule 7.7.1(b) and section 9A(3)(b) of the *Corporations Act 2001* (Cth), the Company wishes to advise you that it will not be extending the Entitlement Offer to you and you will not be able to subscribe for new shares under the Entitlement Offer. However, as the Entitlement Offer is renounceable, you may receive value for entitlements you would have received had you been eligible to participate in the Entitlement Offer, which is explained further below.

What will happen to the new shares that I would have been entitled to subscribe for if I was an Eligible Shareholder?

The Company will appoint a nominee to arrange for the sale of the entitlements which would have been granted to you under the Entitlement Offer (**Sale Nominee**).

The Company will issue the entitlements to the Sale Nominee that would otherwise have been issued to you. The Sale Nominee will not be subscribing for the new shares but may dispose of the entitlements at any price necessary to any buyer, it is, at its discretion, able to procure.



The Sale Nominee will have the absolute discretion to determine the timing and the price at which your entitlements may be sold and the manner of any such sale.

Subject to it being economic to do so, any net proceeds of sale will be distributed (net of expenses) to each of those Ineligible Shareholders for whose benefit the entitlements are sold in proportion to the Ineligible Shareholders' entitlement.

Please note that neither the Company nor the Sale Nominee will be held liable for the sale of such Entitlements at any particular price or the timing of such sale. If the Sale Nominee forms the reasonable opinion that there is not a viable market for such entitlements or a surplus of sale proceeds over expenses from the sale cannot be obtained in relation to the sale of such entitlements, those entitlements will be allowed to lapse. No money will be payable to you in such circumstances.

On behalf of the directors and management of the Company, we regret that you are not eligible to participate in the Entitlement Offer and thank you for your continued support.

Yours sincerely

Dr Michael Monsour

Chairman

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:



About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale from pericoach.com in Australia and New Zealand, UK and Ireland, and in the USA.

